TVTX•benzinga•
JP Morgan Maintains Overweight on Travere Therapeutics, Raises Price Target to $44
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 26, 2025 by benzinga